So turmeric you have not received an email back from DD? But DD has replied to psychic's email.
Replies to one and not others?
Printable View
So turmeric you have not received an email back from DD? But DD has replied to psychic's email.
Replies to one and not others?
I stand by my original viewpoint, PDFs or it didn't happen.
If DD knows about the incorrect comments then PEB should have cleared this up. It is material information.
Well that is interesting, although I'd like to see the question to the answer, it may be that the ODT do actually have a case to answer in misleading the market.
Pacific Edge have done some market research in the past, as was presented directly by them in 2011. However, it has often been a point of peculiarity for me that they haven’t engaged Edison or a similar investment analyst to work with them on a full valuation work up.
Still, I think they are doing the right thing now, and if this is indeed actually a real email, it is really quite good news as increasingly going forward it will otherwise get harder for analysts to assess.
I've been working in the background over the last couple of weeks to assess the value of Cxbladder(triage), due for launch any day now, and I can honestly say that without direct access to information from Pacific Edge it is something that is quite difficult to do at all with clatity.
Turm, I think you need to read my initial position on this whole saga again.
I raised the issue of why hasn't there been a retraction of the 'tens of thousands' statement via the NZX, instead of to individuals, after reading Black knats post. Robbo asked for proof from BK, which I then thought was a fair enough point. I have not said anymore since, patiently waiting for a company reply, whilst the machine raged on.
Actually, I thought MAC's QED post was a logical summation of why they hadn't retracted publically, but now even he seems disappointed by the 'Dave' email.
It now seems everyone is where I was on Tuesday morning!
New Guy .....now we will get a raft of posts defending these guys. Hancocks is one I can already see smoke coming out his ears.
I have the same doubts as you do and would add in ability to successfully commercialise what they have developed (esp in the US)
I take some comfort in Balance reminding me that the Board acknowledged some of these deficiencies and have beefed up capability with having this US Board
Only my view ....only time will tell how it all turns out
At the end of the day the markets probably already priced in a smaller than anticipated number of tests at around the $1 level,if expectations are exceeded then expect the price to head back toward the $1.50 ish mark so all good aye
Ironically too, in the prospective big picture of what Pacific Edge have told us directly, tens of thousands of tests in 2014 isn’t far off what most analysts seem to be thinking anyway.
Harbour Asset Management have this logarithmic projection indicating around NZ$7.5M in revenues for FY14. At a price point of US$550, this equates to 13,363 sales.
Personally, IMHO I think that this is very much on the high side, but as we know the consensus on this thread is for somewhere between 1,000 and 20,000.
Attachment 5753
Which raises the obvious question. How many tests "x" have been done to produce sales "y" for a ratio of "z" which should fall as time goes on.
Very well articulated Black Knat.
It is a very complex industry and company to analyse. The whole industry seems to have a “patient confidentiality” or a guarded kind of feel toward information disclosure, and David Darling seems very much of this ilk. It’s no wonder that the market jumps on every skerric of pertinent information discovered.
Hopefully Pacific Edge will now find a balanced analyst that will do a full open valuation work up and not just play compare the US company metrics.
I’m hopeful too for quarterly reporting, if no one else raises this at the AGM I think I might.